"T-Lymphocytes, Cytotoxic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2.
| Descriptor ID |
D013602
|
| MeSH Number(s) |
A11.118.637.555.283.875 A11.118.637.555.567.550.500.200 A11.118.637.555.567.569.220.200 A11.118.637.555.567.569.500.200 A15.145.229.637.555.283.875 A15.145.229.637.555.567.550.500.200 A15.145.229.637.555.567.569.220.200 A15.145.229.637.555.567.569.500.200 A15.382.490.555.283.875 A15.382.490.555.567.550.500.200 A15.382.490.555.567.569.220.200 A15.382.490.555.567.569.500.200
|
| Concept/Terms |
T-Lymphocytes, Cytotoxic- T-Lymphocytes, Cytotoxic
- Cytotoxic T-Lymphocyte
- T Lymphocytes, Cytotoxic
- T-Lymphocyte, Cytotoxic
- Cell-Mediated Lympholytic Cells
- Cell Mediated Lympholytic Cells
- Cell, Cell-Mediated Lympholytic
- Cell-Mediated Lympholytic Cell
- Cells, Cell-Mediated Lympholytic
- Lympholytic Cell, Cell-Mediated
- Lympholytic Cells, Cell-Mediated
- Cytotoxic T-Lymphocytes
- Cytotoxic T Lymphocytes
TC2 Cells- TC2 Cells
- Cell, TC2
- Cells, TC2
- TC2 Cell
TC1 Cells- TC1 Cells
- Cell, TC1
- Cells, TC1
- TC1 Cell
|
Below are MeSH descriptors whose meaning is more general than "T-Lymphocytes, Cytotoxic".
- Anatomy [A]
- Cells [A11]
- Blood Cells [A11.118]
- Leukocytes [A11.118.637]
- Leukocytes, Mononuclear [A11.118.637.555]
- Cytokine-Induced Killer Cells [A11.118.637.555.283]
- T-Lymphocytes, Cytotoxic [A11.118.637.555.283.875]
- Lymphocytes [A11.118.637.555.567]
- Lymphocyte Subsets [A11.118.637.555.567.550]
- T-Lymphocyte Subsets [A11.118.637.555.567.550.500]
- T-Lymphocytes, Cytotoxic [A11.118.637.555.567.550.500.200]
- T-Lymphocytes [A11.118.637.555.567.569]
- CD8-Positive T-Lymphocytes [A11.118.637.555.567.569.220]
- T-Lymphocytes, Cytotoxic [A11.118.637.555.567.569.220.200]
- T-Lymphocyte Subsets [A11.118.637.555.567.569.500]
- T-Lymphocytes, Cytotoxic [A11.118.637.555.567.569.500.200]
- Hemic and Immune Systems [A15]
- Blood [A15.145]
- Blood Cells [A15.145.229]
- Leukocytes [A15.145.229.637]
- Leukocytes, Mononuclear [A15.145.229.637.555]
- Cytokine-Induced Killer Cells [A15.145.229.637.555.283]
- T-Lymphocytes, Cytotoxic [A15.145.229.637.555.283.875]
- Lymphocytes [A15.145.229.637.555.567]
- Lymphocyte Subsets [A15.145.229.637.555.567.550]
- T-Lymphocyte Subsets [A15.145.229.637.555.567.550.500]
- T-Lymphocytes, Cytotoxic [A15.145.229.637.555.567.550.500.200]
- T-Lymphocytes [A15.145.229.637.555.567.569]
- CD8-Positive T-Lymphocytes [A15.145.229.637.555.567.569.220]
- T-Lymphocytes, Cytotoxic [A15.145.229.637.555.567.569.220.200]
- T-Lymphocyte Subsets [A15.145.229.637.555.567.569.500]
- T-Lymphocytes, Cytotoxic [A15.145.229.637.555.567.569.500.200]
- Immune System [A15.382]
- Leukocytes [A15.382.490]
- Leukocytes, Mononuclear [A15.382.490.555]
- Cytokine-Induced Killer Cells [A15.382.490.555.283]
- T-Lymphocytes, Cytotoxic [A15.382.490.555.283.875]
- Lymphocytes [A15.382.490.555.567]
- Lymphocyte Subsets [A15.382.490.555.567.550]
- T-Lymphocyte Subsets [A15.382.490.555.567.550.500]
- T-Lymphocytes, Cytotoxic [A15.382.490.555.567.550.500.200]
- T-Lymphocytes [A15.382.490.555.567.569]
- CD8-Positive T-Lymphocytes [A15.382.490.555.567.569.220]
- T-Lymphocytes, Cytotoxic [A15.382.490.555.567.569.220.200]
- T-Lymphocyte Subsets [A15.382.490.555.567.569.500]
- T-Lymphocytes, Cytotoxic [A15.382.490.555.567.569.500.200]
Below are MeSH descriptors whose meaning is more specific than "T-Lymphocytes, Cytotoxic".
This graph shows the total number of publications written about "T-Lymphocytes, Cytotoxic" by people in this website by year, and whether "T-Lymphocytes, Cytotoxic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1998 | 2 | 0 | 2 |
| 1999 | 1 | 0 | 1 |
| 2000 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
| 2008 | 3 | 2 | 5 |
| 2009 | 1 | 1 | 2 |
| 2010 | 1 | 1 | 2 |
| 2011 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2017 | 1 | 1 | 2 |
| 2018 | 0 | 2 | 2 |
| 2021 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "T-Lymphocytes, Cytotoxic" by people in Profiles.
-
Adrenergic receptor signaling regulates the CD40-receptor mediated anti-tumor immunity. Front Immunol. 2023; 14:1141712.
-
Altered regulation of DPF3, a member of the SWI/SNF complexes, underlies the 14q24 renal cancer susceptibility locus. Am J Hum Genet. 2021 09 02; 108(9):1590-1610.
-
Anti-CD73 and anti-OX40 immunotherapy coupled with a novel biocompatible enzyme prodrug system for the treatment of recurrent, metastatic ovarian cancer. Cancer Lett. 2018 07 01; 425:174-182.
-
TriCurin, a synergistic formulation of curcumin, resveratrol, and epicatechin gallate, repolarizes tumor-associated macrophages and triggers an immune response to cause suppression of HPV+ tumors. Cancer Immunol Immunother. 2018 May; 67(5):761-774.
-
T cells from patients with Parkinson's disease recognize a-synuclein peptides. Nature. 2017 06 29; 546(7660):656-661.
-
Altered populations of natural killer cells, cytotoxic T lymphocytes, and regulatory T cells in major depressive disorder: Association with sleep disturbance. Brain Behav Immun. 2017 Nov; 66:193-200.
-
The CD169 sialoadhesin molecule mediates cytotoxic T-cell responses to tumour apoptotic vesicles. Immunol Cell Biol. 2016 05; 94(5):430-8.
-
Role of fatty-acid synthesis in dendritic cell generation and function. J Immunol. 2013 May 01; 190(9):4640-9.
-
The role of MHC class I allele Mamu-A*07 during SIV(mac)239 infection. Immunogenetics. 2011 Dec; 63(12):789-807.
-
Loss of the type I interferon pathway increases vulnerability of mice to genital herpes simplex virus 2 infection. J Virol. 2011 Feb; 85(4):1625-33.